BGB-LC-201
Active, not recruiting
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Study ID 
BGB-LC-201
ClinicalTrials.gov ID
EudraCT Number
2022-502738-18-00
China Drug Trials ID
CTR20230892
Study Overview
Sex:
All
Age: 18 Years / N/A
No Study Documents
Study Overview
Sex:
All
Age: 18 Years / N/A
No Study Documents